



Pfizer ApS  
Lautrupvang 8  
DK-2750 Ballerup  
Tlf.: 44 20 11 00  
Fax: 44 20 11 02  
www.pfizer.dk  
CVR.nr. 66351912  
Pfizer Danmark

Århus Universitetshospital  
Klinisk Epidemiologisk afdeling  
Olof Palmes Allé 43-45  
8200 Aarhus N  
Att.: Søren Paaske Johnsen

29<sup>th</sup> February 2016

**Agreement on support to project "Time trends in preadmission use of OAC and clinical outcome among atrial fibrillation patients admitted with acute stroke", covering expenses for salary for a junior researcher, biostatistician, senior researcher, data and publication fees.**

By request of Søren Paaske Johnsen, Department of Clinical Epidemiology, Pfizer is very pleased to confirm that it will provide support to the above-mentioned research project in the form of 250,000 DKK.

The support will be given to Department of Clinical Epidemiology and is approved by Henrik Toft Sørensen on behalf of Aarhus University Hospital.

The research project will be executed by Department of Clinical Epidemiology through its employee Søren Paaske Johnsen, Associate Professor, PhD.

The purpose of the research project is in a cross sectional and follow up study to examine through Danish registries time trends in preadmission use of OAC (any type) and specific OACs in patients with AF, who are admitted with stroke. Also stroke severity and mortality by treatment will be examined and Pfizer wishes to support this purpose.

Department of Clinical Epidemiology will ensure that the support is used solely for professional and scientific purposes in relation to the research project and undertakes that any surplus from the support not used in accordance herewith will be refunded.

Upon request from Pfizer the Hospital must document that the support is spend in accordance with the above-mentioned.

Department of Clinical Epidemiology undertakes the full responsibility for the execution of the research project and Pfizer disclaims every right to interfere with the execution and any other part of the research project.

Furthermore Department of Clinical Epidemiology will be responsible for compliance with all applicable law.

Pfizer shall not be liable for damages of any kind and Pfizer provides no indemnification of any type.

We kindly ask you to return the signed agreement to Pfizer ApS in the enclosed envelope.

Please complete and sign the attached Payment Form and return to Pfizer ApS as soon as possible together with the signed agreement. Please note that Pfizer will be precluded from providing you with the financial support if you do not state a CVR-number on the Payment Form.

This agreement will be available on Pfizer's webpage ([www.pfizer.dk](http://www.pfizer.dk)) when the support is granted and for a period of 2 years thereafter.

Information regarding name and contact information in relation to this agreement will be stored in a Pfizer global electronic system. You should be aware that some of the members of Pfizer group, legal counsel and/or regulatory authorities could have access to information as described above are located in countries whose laws protecting personal information may not be equivalent to those in your country. In particular, personal data disclosed to Pfizer Inc. by members of the Pfizer group within the European Economic Area and Switzerland are protected by Pfizer Inc.'s participation in the "safe harbour" schemes administered by the U.S. Department of Commerce.


You have right to access or, where incorrect, amend information pertaining to you that is in Pfizer's possession.


The support is provided under the provisions set forth in this agreement and in accordance with Pfizer's anti-corruption provisions (Appendix A).

By signing this page, the Requester confirms that the Requester has read and understood Pfizer's policy relating to bribery and corruption pursuant to appendix A and that the support is spend in accordance with the above mentioned terms and conditions.

Date: 26/3. 2016  
Signature of authorized signatory on behalf of Pfizer ApS:  
  
Troels Reiche  
Medical Director

  
Søren Paaske Johnsen  
Associate Professor, PhD

Date:  
Signature of authorized signatory on behalf of Aarhus University Hospital:  
  
Henrik Toft Sørensen  
Professor, MD, PhD

Accepted by: 9/5-16  
  
Name: Kristjar Skajaa  
Title: Head of Department of Clinical Medicine, Aarhus University

## Appendix A – Standard Anti-Corruption Provisions

- 1.1 The financial support from Pfizer will not cause your entity and, to your knowledge, any individuals affiliated with your entity or this support, to do anything that would result in Pfizer improperly obtaining or retaining business or gaining any improper business advantage;
- 1.2 Neither your entity and, to your knowledge, any individuals affiliated with your entity or this support, will use any portion of the financial support from Pfizer to directly or indirectly offer or pay any money or anything of value in an effort to influence any Government Official or any other person in order for Pfizer to improperly obtain or retain business or to gain an improper business advantage, and, have not accepted, and will not accept in the future, such a payment; and
- 1.3 Pfizer will be entitled to revoke or suspend any financial support if Pfizer learns that your entity or any individuals affiliated with your entity or this support, has used or intend[s] to use any portion of the support to improperly seek to influence any Government Official or any other person in order to obtain or retain business or gain a business advantage.
- 1.4 Pfizer may at any time publicly disclose that it has provided you with financial support, including the amount of such support.